Cadila Healthcare Limited

Viviana Gianino

Martin Billeter

Reinhard Glueck

Agata Fazio

A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding severalantigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of, the merozoite surface protein 1 (MSP-1) of, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.

Growing community of inventors

Catania, Italy

Viviana Gianino